Michael Weickert
Chief Executive Officer Pacylex Pharmaceuticals
Seminars
Thursday 5th November 2026
Unlocking NMT Inhibitors as a Novel ADC Payload Class Beyond Conventional Cytotoxic Mechanisms
12:00 pm
- Review new clinical and mechanistic data from the most advanced NMT inhibitor, zelenirstat, and examine how emerging efficacy, safety, and biological activity findings are helping validate NMT inhibition as a promising ADC payload mechanism
- Explore the biology underpinning NMT inhibition, including emerging understanding of isozyme dependency in cancer cells and why NMT1 represents an attractive and potentially selective therapeutic vulnerability
- Assess why growing biological, clinical, and translational evidence is increasing interest in NMT inhibitors as ADC payloads, and discuss how the mechanism could be deployed to address resistance and enable greater payload differentiation beyond conventional cytotoxic approaches
